VERONICA CARRERA: Open Payments
NPI 1902547177 · SAN ANTONIO, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,284 in 34 payments from 10 companies in 2025. Trend: 2023 $2,388 · 2024 $1,765 · 2025 $1,284
Food & beverage: $1,284
| Company | Payments | Amount |
|---|---|---|
| Madrigal Pharmaceuticals | 6 | $461 |
| Lilly USA, LLC | 5 | $203 |
| Ipsen Biopharmaceuticals, Inc | 3 | $159 |
| Phathom Pharmaceuticals, Inc. | 2 | $123 |
| ABBVIE INC. | 5 | $92 |
| Janssen Biotech, Inc. | 4 | $76 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 3 | $58 |
| Gilead Sciences, Inc. | 3 | $49 |
| Celltrion USA Inc. | 2 | $46 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $18 |
Products named: REZDIFFRA, OMVOH, IQIRVO, VOQUEZNA, TREMFYA, LINZESS, XIFAXAN, VEGZELMA.
Industry payments across TX — which companies pay providers there.
